3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioblastoma
5
Glioma
3
Brain Neoplasms
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Sarcoma
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
2
fluciclovine F-18
2
neratinib
1
alovudine
1
Temozolomide
1
Oncolytic Virotherapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-15
1
Cyclophosphamide
1
Antibodies, Monoclonal
1
ABT-414
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Oncolytic Virotherapy
×
CNS
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled